GlassScriptPhysician profile
Lisa Walters
NPI 1548227937
$8,399.29
in general payments reported to CMS, 2019-2025
36 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $280 · 2021: $745 · 2022: $978 · 2023: $1,801 · 2024: $2,510 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,094 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,093.74 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,457.48 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,196.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $866.49 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.40 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Glaxosmithkline, LLC. | $531.30 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $440.09 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $439.33 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $434.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Idorsia Pharmaceuticals US INC | $356.56 | 2022-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $301.92 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Axsome Therapeutics, INC. | $217.07 | 2024-2025 | Auvelity |
| Scilex Pharmaceuticals INC. | $194.38 | 2024-2025 | |
| Pfizer INC. | $167.58 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.47 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $127.17 | 2022-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $120.59 | 2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $118.88 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.16 | 2022-2024 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $87.80 | 2021 | |
| Abbott Laboratories | $85.19 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $53.47 | 2021-2023 | Nexletol |
| Exact Sciences Corporation | $51.12 | 2023-2024 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $43.81 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Vivus LLC | $34.72 | 2023-2024 | Qsymia |
| Corcept Therapeutics | $33.99 | 2023 | Korlym |
| Vanda Pharmaceuticals INC. | $30.76 | 2025 | Ponvory |
| Sanofi-Aventis U.S. LLC | $25.00 | 2020 | |
| Eisai INC. | $24.01 | 2025 | |
| Inspire Medical Systems, INC. | $23.41 | 2024 | Inspire |
| Sumitomo Pharma America, INC. | $21.56 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $21.33 | 2024 | Heplisav-B |
| Regeneron Healthcare Solutions, INC. | $21.27 | 2025 | Evkeeza |
| Bausch Health US, LLC | $20.84 | 2024 | Aplenzin |
| Dexcom, INC. | $19.97 | 2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $18.61 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.02 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.